Table 1.
Baseline characteristics by allocated planning method
| Standard planning, n = 32 | Adaptive planning, n = 33 | Total, n = 65 | |
|---|---|---|---|
| Age, years | 84.8 (80.7-88.9) | 84.1 (80.4-87.1) | 84.5 (80.6-88.6) |
| Months from histologic confirmation to randomization | 1.7 (1.2-2.1) | 1.4 (1.0-2.1) | 1.6 (1.1-2.1) |
| Sex | |||
| Male | 24 (75%) | 20 (61%) | 44 (68%) |
| Female | 8 (25%) | 13 (39%) | 21 (32%) |
| Extent of resection | |||
| Biopsy | 10 (31%) | 10 (30%) | 20 (31%) |
| Partial resection | 10 (31%) | 13 (39%) | 23 (35%) |
| Full resection | 11 (34%) | 9 (27%) | 20 (31%) |
| Unknown/missing | 1 (3%) | 1 (3%) | 2 (3%) |
| Multiple tumors | |||
| Yes | 6 (19%) | 7 (21%) | 13 (20%) |
| No | 26 (81%) | 26 (79%) | 52 (80%) |
| Histologic tumor type | |||
| Urothelial | 31 (97%) | 32 (97%) | 63 (97%) |
| Nonurothelial | 1 (3%) | 1 (3%) | 2 (3%) |
| Grade | |||
| G2 | 1 (3%) | 0 (0%) | 1 (2%) |
| G3 | 31 (97%) | 33 (100%) | 64 (98%) |
| CIS present | |||
| Yes | 9 (28%) | 11 (33%) | 20 (31%) |
| No | 22 (69%) | 22 (67%) | 44 (68%) |
| Unknown/missing | 1 (3%) | 0 (0%) | 1 (2%) |
| Clinical stage | |||
| T2 | 24 (75%) | 21 (64%) | 45 (69%) |
| T3a | 1 (3%) | 5 (15%) | 6 (9%) |
| T3b | 5 (16%) | 5 (15%) | 10 (15%) |
| T4a | 2 (6%) | 2 (6%) | 4 (6%) |
| NM stage | |||
| N0/M0 | 32 (100%) | 33 (100%) | 65 (100%) |
| Age adjusted Charlson Comorbidity index score | |||
| 5 | 1 (3%) | 0 (0%) | 1 (2%) |
| 6 | 14 (44%) | 13 (39%) | 27 (42%) |
| 7 | 11 (34%) | 5 (15%) | 16 (25%) |
| 8 | 4 (13%) | 6 (18%) | 10 (15%) |
| 9 | 2 (6%) | 8 (24%) | 10 (15%) |
| 10 | 0 (0%) | 0 (0%) | 0 (0%) |
| 11 | 0 (0%) | 1 (3%) | 1 (2%) |
Abbreviation: CIS = carcinoma in situ; IQR = interquartile range; NM stage = nodal/metastatic stage.
Data are shown as n (%) or median (IQR).